Supplemental Table 10. Baseline characteristic between dose levels of steroid use per day in matched patients without steroid prior to cardiac arrest

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | Non- steroid |  | 1st Quartile |  | 2nd Quartile |  | 3rd Quartile |  | 4th Quartile |
| **Baseline characterisitics** |  | n=3248 |  | n=811 |  | n=864 |  | n=761 |  | n=812 |
|  |  | n(%) |  | n(%) |  | n(%) |  | n(%) |  | n(%) |
| Age (years) |  | 66.39±17.62 |  | 65.18±16.52 |  | 66.03±17.50 |  | 67.12±16.84 |  | 67.05±17.32 |
| Gender (Male) |  | 1924 (59.24%) |  | 510 (62.89%) |  | 497 (57.52%) |  | 438 (57.56%) |  | 491 (60.47%) |
| Presenting complaint | |  |  |  |  |  |  |  |  |  |
|  | Cardiac event | 656 (20.2%) |  | 194 (23.92%) |  | 178 (20.6%) |  | 131 (17.21%) |  | 152 (18.72%) |
|  | Respiratory event | 354 (10.9%) |  | 94 (11.59%) |  | 79 (9.14%) |  | 92 (12.09%) |  | 90 (11.08%) |
|  | Other event | 714 (21.98%) |  | 214 (26.39%) |  | 193 (22.34%) |  | 141 (18.53%) |  | 151 (18.6%) |
|  | Unknown | 1524 (46.92%) |  | 309 (38.1%) |  | 414 (47.92%) |  | 397 (52.17%) |  | 419 (51.6%) |
| Diabetes mellitus |  | 913 (28.11%) |  | 240 (29.59%) |  | 233 (26.97%) |  | 237 (31.14%) |  | 223 (27.46%) |
| Hypertension |  | 1351 (41.59%) |  | 369 (45.5%) |  | 337 (39%) |  | 336 (44.15%) |  | 316 (38.92%) |
| Coronary artery disease | | 494 (15.21%) |  | 154 (18.99%) |  | 133 (15.39%) |  | 116 (15.24%) |  | 102 (12.56%) |
| Heart failure |  | 275 (8.47%) |  | 84 (10.36%) |  | 71 (8.22%) |  | 69 (9.07%) |  | 71 (8.74%) |
| Atrial fibrillation |  | 110 (3.39%) |  | 22 (2.71%) |  | 35 (4.05%) |  | 25 (3.29%) |  | 27 (3.33%) |
| Chronic kidney disease | | 281 (8.65%) |  | 97 (11.96%) |  | 68 (7.87%) |  | 76 (9.99%) |  | 52 (6.4%) |
| Malignancy |  | 185 (5.7%) |  | 47 (5.8%) |  | 52 (6.02%) |  | 41 (5.39%) |  | 49 (6.03%) |
| Chronic obstructive lung disease | | 293 (9.02%) |  | 68 (8.38%) |  | 80 (9.26%) |  | 76 (9.99%) |  | 92 (11.33%) |
| Asthma |  | 86 (2.65%) |  | 5 (0.62%) |  | 20 (2.31%) |  | 26 (3.42%) |  | 31 (3.82%) |
| Adrenal insufficiency |  | 4 (0.12%) |  | . (.%) |  | . (.%) |  | 2 (0.26%) |  | 4 (0.49%) |
| Autoimmune disease |  | 14 (0.43%) |  | 1 (0.12%) |  | 7 (0.81%) |  | 7 (0.92%) |  | 3 (0.37%) |
| Shockable rhythm |  | 809 (24.91%) |  | 251 (30.95%) |  | 226 (26.16%) |  | 178 (23.39%) |  | 179 (22.04%) |
| Epinephrine dosage (mg) | | 5.77±5.33 |  | 4.19±4.64 |  | 5.94±5.74 |  | 6.07±5.57 |  | 6.76±5.69 |
| Vasopressin |  | 9 (0.28%) |  | 3 (0.37%) |  | 1 (0.12%) |  | . (.%) |  | 10 (1.23%) |
| Medical center |  | 996 (30.67%) |  | 225 (27.74%) |  | 278 (32.18%) |  | 249 (32.72%) |  | 227 (27.96%) |
| Urbanization level of residence | |  |  |  |  |  |  |  |  |  |
|  | 1 (high) | 888 (27.34%) |  | 207 (25.52%) |  | 259 (29.98%) |  | 206 (27.07%) |  | 222 (27.34%) |
|  | 2 | 1363 (41.96%) |  | 371 (45.75%) |  | 342 (39.58%) |  | 305 (40.08%) |  | 333 (41.01%) |
|  | 3 | 283 (8.71%) |  | 74 (9.12%) |  | 79 (9.14%) |  | 75 (9.86%) |  | 55 (6.77%) |
|  | ≥ 4 (low) | 714 (21.98%) |  | 159 (19.61%) |  | 184 (21.3%) |  | 175 (23%) |  | 202 (24.88%) |
| Geographic distribution | |  |  |  |  |  |  |  |  |  |
|  | Taipei | 1226 (37.75%) |  | 301 (37.11%) |  | 324 (37.5%) |  | 267 (35.09%) |  | 332 (40.89%) |
|  | Northern | 436 (13.42%) |  | 123 (15.17%) |  | 131 (15.16%) |  | 84 (11.04%) |  | 104 (12.81%) |
|  | Central | 890 (27.4%) |  | 224 (27.62%) |  | 247 (28.59%) |  | 229 (30.09%) |  | 172 (21.18%) |
|  | Southern | 312 (9.61%) |  | 57 (7.03%) |  | 77 (8.91%) |  | 84 (11.04%) |  | 89 (10.96%) |
|  | Kaopin | 220 (6.77%) |  | 71 (8.75%) |  | 55 (6.37%) |  | 57 (7.49%) |  | 62 (7.64%) |
|  | Eastern | 164 (5.05%) |  | 35 (4.32%) |  | 30 (3.47%) |  | 40 (5.26%) |  | 53 (6.53%) |